UCB: set to sell its most mature activities in China

(CercleFinance.com) - Belgian pharmaceutical company UCB announced on Monday that it would be selling its most mature activities in China, i.
e. its portfolio of drugs in the neurology and allergy fields, in order to concentrate on its innovative products.

The group specifies that the scope in question includes licenses for the anti-epileptics Keppra and Vimpat, the Parkinson's disease treatment Neupro and the antihistamines Zyrtec and Xyzal, as well as a production site in Zhuhai, south of Shenzhen.

Between them, these five drugs generated sales of E131m on the Chinese market last year.

The group will be sold to CBC Group, a Singapore-based asset manager, and Mubadala, an Abu Dhabi investment fund, for a total of $680m.

UCB, which has been present in China for 28 years, explains that it intends to concentrate its activities in China on the launch of new treatments in immunology, neurology and rare diseases.

The transaction is expected to be finalised in Q4.

UCB shares on the Brussels Stock Exchange reacted little to this announcement on Monday morning, up just 0.2%, against a 0.1% rise in the BEL 20 index.


Copyright (c) 2024 CercleFinance.com. All rights reserved.